First Palatable Elemental Diet Effective at Managing SIBO, Peer-Reviewed Clinical Study Confirms
mBIOTA Labs, an emerging medical food company revolutionizing medical nutrition for the management of gastrointestinal (GI) conditions, highlights expanded data findings from its prospective clinical trial indicating that its flagship product, mBIOTA Elemental™ diet, is a highly effective solution for the management of gastrointestinal disorders, specifically Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO). The clinical research findings are published in Clinical Gastroenterology and Hepatology, awarded by the 2024 American College of Gastroenterology Annual Meeting, and were presented at the 2024 Digestive Disease Week and internationally at the 2024 Federation of Neurogastroenterology and Motility Meeting.
mBIOTA Labs Announces Results from First Prospective Clinical Trial of Novel, Palatable Elemental Diet in Patients with SIBO and IMO
mBIOTA Labs, a medical food company revolutionizing oral nutrition through their proprietary palatable elemental diet, mBIOTA Elemental™, today announced the initial study results of their first prospective clinical trial assessing the efficacy of the mBIOTA Elemental™ diet in patients with small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), or a combination of the two.
